Cargando…
A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice
Safinamide is an approved drug for the treatment of motor fluctuations in Parkinson’s disease (PD). Scarce data are available on its use in clinical practice. A group of Spanish movement disorders specialists was convened to review the use of safinamide across different clinical scenarios that may g...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139287/ https://www.ncbi.nlm.nih.gov/pubmed/32197462 http://dx.doi.org/10.3390/brainsci10030176 |
_version_ | 1783518731029184512 |
---|---|
author | Pagonabarraga, Javier Arbelo, José Matías Grandas, Francisco Luquin, Maria-Rosario Martínez Martín, Pablo Rodríguez-Oroz, Mari Cruz Valldeoriola, Francesc Kulisevsky, Jaime |
author_facet | Pagonabarraga, Javier Arbelo, José Matías Grandas, Francisco Luquin, Maria-Rosario Martínez Martín, Pablo Rodríguez-Oroz, Mari Cruz Valldeoriola, Francesc Kulisevsky, Jaime |
author_sort | Pagonabarraga, Javier |
collection | PubMed |
description | Safinamide is an approved drug for the treatment of motor fluctuations in Parkinson’s disease (PD). Scarce data are available on its use in clinical practice. A group of Spanish movement disorders specialists was convened to review the use of safinamide across different clinical scenarios that may guide neurologists in clinical practice. Eight specialists with recognized expertise in PD management elaborated the statements based on available evidence in the literature and on their clinical experience. The RAND/UCLA method was carried, with final conclusions accepted after a 2-round modified Delphi process. Higher level of agreement between panellists was reached for the following statements. Safinamide significantly improves mean daily OFF time without troublesome dyskinesias. Adjunctive treatment with safinamide is associated with motor improvements in patients with mid-to-late PD. The efficacy of safinamide on motor fluctuations is maintained at long-term, with no increase over time in dyskinesias severity. The clinical benefits of safinamide on pain and depression remain unclear. Safinamide presents a similar incidence of adverse events compared with placebo. The efficacy and safety of safinamide shown in the pivotal clinical trials are reproduced in clinical practice, with improvement of parkinsonian symptoms, decrease of daily OFF time, control of dyskinesias at the long term, and good tolerability and safety. |
format | Online Article Text |
id | pubmed-7139287 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-71392872020-04-10 A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice Pagonabarraga, Javier Arbelo, José Matías Grandas, Francisco Luquin, Maria-Rosario Martínez Martín, Pablo Rodríguez-Oroz, Mari Cruz Valldeoriola, Francesc Kulisevsky, Jaime Brain Sci Review Safinamide is an approved drug for the treatment of motor fluctuations in Parkinson’s disease (PD). Scarce data are available on its use in clinical practice. A group of Spanish movement disorders specialists was convened to review the use of safinamide across different clinical scenarios that may guide neurologists in clinical practice. Eight specialists with recognized expertise in PD management elaborated the statements based on available evidence in the literature and on their clinical experience. The RAND/UCLA method was carried, with final conclusions accepted after a 2-round modified Delphi process. Higher level of agreement between panellists was reached for the following statements. Safinamide significantly improves mean daily OFF time without troublesome dyskinesias. Adjunctive treatment with safinamide is associated with motor improvements in patients with mid-to-late PD. The efficacy of safinamide on motor fluctuations is maintained at long-term, with no increase over time in dyskinesias severity. The clinical benefits of safinamide on pain and depression remain unclear. Safinamide presents a similar incidence of adverse events compared with placebo. The efficacy and safety of safinamide shown in the pivotal clinical trials are reproduced in clinical practice, with improvement of parkinsonian symptoms, decrease of daily OFF time, control of dyskinesias at the long term, and good tolerability and safety. MDPI 2020-03-18 /pmc/articles/PMC7139287/ /pubmed/32197462 http://dx.doi.org/10.3390/brainsci10030176 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pagonabarraga, Javier Arbelo, José Matías Grandas, Francisco Luquin, Maria-Rosario Martínez Martín, Pablo Rodríguez-Oroz, Mari Cruz Valldeoriola, Francesc Kulisevsky, Jaime A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice |
title | A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice |
title_full | A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice |
title_fullStr | A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice |
title_full_unstemmed | A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice |
title_short | A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice |
title_sort | spanish consensus on the use of safinamide for parkinson’s disease in clinical practice |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139287/ https://www.ncbi.nlm.nih.gov/pubmed/32197462 http://dx.doi.org/10.3390/brainsci10030176 |
work_keys_str_mv | AT pagonabarragajavier aspanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice AT arbelojosematias aspanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice AT grandasfrancisco aspanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice AT luquinmariarosario aspanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice AT martinezmartinpablo aspanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice AT rodriguezorozmaricruz aspanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice AT valldeoriolafrancesc aspanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice AT kulisevskyjaime aspanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice AT pagonabarragajavier spanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice AT arbelojosematias spanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice AT grandasfrancisco spanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice AT luquinmariarosario spanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice AT martinezmartinpablo spanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice AT rodriguezorozmaricruz spanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice AT valldeoriolafrancesc spanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice AT kulisevskyjaime spanishconsensusontheuseofsafinamideforparkinsonsdiseaseinclinicalpractice |